000127935 001__ 127935
000127935 005__ 20240228135037.0
000127935 0247_ $$2doi$$a10.1002/ijc.28866
000127935 0247_ $$2pmid$$apmid:24676718
000127935 0247_ $$2ISSN$$a0020-7136
000127935 0247_ $$2ISSN$$a1097-0215
000127935 037__ $$aDKFZ-2017-03957
000127935 041__ $$aeng
000127935 082__ $$a610
000127935 1001_ $$0P:(DE-HGF)0$$aMeides, Alice$$b0$$eFirst author
000127935 245__ $$aEffects of selective MMP-13 inhibition in squamous cell carcinoma depend on estrogen.
000127935 260__ $$aBognor Regis$$bWiley-Liss$$c2014
000127935 3367_ $$2DRIVER$$aarticle
000127935 3367_ $$2DataCite$$aOutput Types/Journal article
000127935 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521198648_1713
000127935 3367_ $$2BibTeX$$aARTICLE
000127935 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127935 3367_ $$00$$2EndNote$$aJournal Article
000127935 520__ $$aMatrix metalloproteinases like MMP-13 cleave and remodel the extracellular matrix and thereby play a crucial role in tumor progression in vivo. Using a highly selective inhibitor to block MMP-13 protein activity, we demonstrate a striking inhibitory effect on invasive tumor growth and vascularization in murine skin squamous cell carcinoma (SCC). Therapy outcome critically depends on animal age in C57Bl/6 mice and was successful in old female but not in young female mice. Treatment success was recovered by ovariectomy in young and abolished by 17ß-estradiol supplementation in old mice, suggesting a hormone dependent inhibitor effect. Responsiveness of the tumorigenic keratinocytes BDVII and fibroblasts to 17ß-estradiol was confirmed in vitro, where MMP-13 inhibitor treatment led to a reduction of cell invasion and vascular endothelial growth factor (VEGF) release. This correlated well with a less invasive and vascularized tumor in treated mice in vivo. 17ß-estradiol supplementation also reduced invasion and VEGF release in vitro with no additional reduction on MMP-13 inhibitor treatment. This suggests that low 17ß-estradiol levels in old mice in vivo lead to enhanced MMP-13 levels and VEGF release, allowing a more effective inhibitor treatment compared to young mice. In our study, we present a strong link between lower estrogen levels in old female mice, an elevated MMP-13 level, which results in a more effective MMP-13 inhibitor treatment in fibroblasts and SCC cells in vitro and in vivo.
000127935 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000127935 588__ $$aDataset connected to CrossRef, PubMed,
000127935 650_7 $$2NLM Chemicals$$aEstrogens
000127935 650_7 $$2NLM Chemicals$$aMatrix Metalloproteinase Inhibitors
000127935 650_7 $$2NLM Chemicals$$aVascular Endothelial Growth Factor A
000127935 650_7 $$04TI98Z838E$$2NLM Chemicals$$aEstradiol
000127935 650_7 $$0EC 3.4.24.-$$2NLM Chemicals$$aMatrix Metalloproteinase 13
000127935 7001_ $$0P:(DE-HGF)0$$aGutschalk, Claudia M$$b1
000127935 7001_ $$aDevel, Laurent$$b2
000127935 7001_ $$aBeau, Fabrice$$b3
000127935 7001_ $$aCzarny, Bertrand$$b4
000127935 7001_ $$aHensler, Sabine$$b5
000127935 7001_ $$0P:(DE-He78)4541e7361856fcd146b8014607f8da8a$$aNeugebauer, Julia$$b6$$udkfz
000127935 7001_ $$aDive, Vincent$$b7
000127935 7001_ $$0P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aAngel, Peter$$b8$$udkfz
000127935 7001_ $$0P:(DE-HGF)0$$aMueller, Margareta M$$b9$$eLast author
000127935 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.28866$$gVol. 135, no. 12, p. 2749 - 2759$$n12$$p2749 - 2759$$tInternational journal of cancer$$v135$$x0020-7136$$y2014
000127935 909CO $$ooai:inrepo02.dkfz.de:127935$$pVDB
000127935 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127935 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127935 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4541e7361856fcd146b8014607f8da8a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127935 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000127935 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000127935 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000127935 9141_ $$y2014
000127935 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127935 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127935 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127935 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127935 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000127935 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127935 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127935 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127935 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127935 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127935 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127935 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000127935 9201_ $$0I:(DE-He78)A101-20160331$$kA101$$lTumor- und Mikroumgebung$$x0
000127935 9201_ $$0I:(DE-He78)A100-20160331$$kA100$$lSignaltransduktion/Wachstumskontrolle$$x1
000127935 980__ $$ajournal
000127935 980__ $$aVDB
000127935 980__ $$aI:(DE-He78)A101-20160331
000127935 980__ $$aI:(DE-He78)A100-20160331
000127935 980__ $$aUNRESTRICTED